AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
申请人:Shionogi Co., Ltd.
公开号:EP1911759A1
公开(公告)日:2008-04-16
The present invention creates an azaindole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further providing a therapeutic agent for treating allergic diseases.
A compound of the general formula (I)
wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X1=X2-X3=X4- is a formula of -C(R1)=C(R2)-C(R3)=N- etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6 is optionally substituted C1-C6 alkyloxy etc.; R7 is independently a halogen atom etc.; R8 is optionally substituted C1-C6 alky etc.; R9 is carboxy etc.; M is sulfonyl etc.; Y is a single bond etc.; L1, L2 and L3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.
Azaindole Derivative Having PGD2 Receptor Antagonistic Activity
申请人:Kugimiya Akira
公开号:US20090197881A1
公开(公告)日:2009-08-06
The present invention creates an azaindole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further providing a therapeutic agent for treating allergic diseases.
A compound of the general formula (I)
wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X
1
=X
2
-X
3
=X
4
- is a formula of —C(R
1
)═C(R
2
)—C(R
3
)═N— etc.; R
1
, R
2
, R
3
, R
4
and R
5
are independently a hydrogen atom or a halogen atom etc.; R
6
is optionally substituted C1-C6 alkyloxy etc.; R
7
is independently a halogen atom etc.; R
8
is optionally substituted C1-C6 alky etc.; R
9
is carboxy etc.; M is sulfonyl etc.; Y is a single bond etc.; L
1
, L
2
and L
3
are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.